[HTML][HTML] Modeling the tumor microenvironment and cancer immunotherapy in next-generation humanized mice

A Chen, I Neuwirth, D Herndler-Brandstetter - Cancers, 2023 - mdpi.com
Simple Summary A bottleneck in oncology is the translation of results from preclinical
models to the clinics. The rate of anticancer drugs that are effective in preclinical studies but …

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice

A Chen, I Neuwirth, D Herndler-Brandstetter - Cancers, 2023 - search.proquest.com
Cancer immunotherapy has brought significant clinical benefits to numerous patients with
malignant disease. However, only a fraction of patients experiences complete and durable …

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice.

A Chen, I Neuwirth, D Herndler-Brandstetter - Cancers, 2023 - europepmc.org
Cancer immunotherapy has brought significant clinical benefits to numerous patients with
malignant disease. However, only a fraction of patients experiences complete and durable …

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice

A Chen, I Neuwirth, D Herndler-Brandstetter - Cancers, 2023 - pubmed.ncbi.nlm.nih.gov
Cancer immunotherapy has brought significant clinical benefits to numerous patients with
malignant disease. However, only a fraction of patients experiences complete and durable …

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice.

A Chen, I Neuwirth, D Herndler-Brandstetter - Cancers, 2023 - search.ebscohost.com
Simple Summary: A bottleneck in oncology is the translation of results from preclinical
models to the clinics. The rate of anticancer drugs that are effective in preclinical studies but …

[HTML][HTML] Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice

A Chen, I Neuwirth, D Herndler-Brandstetter - Cancers, 2023 - ncbi.nlm.nih.gov
Cancer immunotherapy has brought significant clinical benefits to numerous patients with
malignant disease. However, only a fraction of patients experiences complete and durable …